Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2019

Other current assets consisted of the following as of September 30, 2019 and December 31, 2018:

	September 30, 2019		December 31, 2018
		(unaudited)
Indemnification assets	$	875	$	875
Prepaid expenses		2,571		1,230
Other		76		65
Total other current assets	$	3,522	$	2,170

Schedule of Weighted Average Number of Shares

A reconciliation of the number of shares of common stock, par value $0.01 per share (the “Common Stock”) used in the calculation of basic and diluted loss per share for the three- and nine-month periods ended September 30, 2019 and 2018 is as follows:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
	(unaudited)
Basic weighted average number of of common shares		38,196		28,215		37,169		28,002
Potential dilutive effect of stock-based awards		-		-		-		-
Diluted weighted average number of common shares		38,196		28,215		37,169		28,002

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2019		2018		2019		2018
	(unaudited)
Options		3,936		2,256		3,936		2,256
Stock-settled stock appreciation rights (SARs)		22		59		22		59
Restricted stock units (RSUs)		544		220		544		220
Warrants		14,196		13,542		14,196		13,542
		18,698		16,077		18,698		16,077